99mTc-MIBI scintigraphy and beta-2-microglobulin in patients with multiple myeloma
|D. Vassileva, A. Tzonevska|
Abstract. Multiple Myeloma is malignancy characterizing with autoimune proliferation of malignant plasma cells. The aim of the study was to investigate the clinical usefulness of 99mTc-MIBI scintigraphy and serum beta-2- microglobulin for diagnosis, staging and therapy control in patients with multiple myeloma. 67 patients with multiple myeloma were investigated. 42 patients were in active state and 25 patients were in remission. Planar images and/or SPECT were performed on the rotating gamma camera (Siemens) 30 minutes and 3 hours after i.v. injection of 555-740 MBq 99mTc-MIBI. The uptake patterns were grouped as normal, diffusely increased and focal increased. Beta-2-microglobulin levels were
measured by radioimmunoassay. The scintigraphy with 99mTc-MIBI was true positive in 40 patients with MM. From them, 21 patients were with diffuse uptake and 19 were with focal uptake with 29 lesions. 99mTc-MIBI marrow uptake correlated with the percentage of bone marrow plasma cells. All samples from patients in active state had a serum beta-2-microglobulin above the normal range. In two patients with false negative scan, the results were compared with the data of CT images. Positive clinical findings and increased value of tumour marker were
found in these patients. One patient was with false positive scintigraphy. After therapy, the scintigraphy was true negative in 25 patients. In these patients in remission, the levels of the serum beta-2-microglobulin were near to the normal levels. In conclusion, our results demonstrated the effectiveness of both methods – 99mTc-MIBI scintigraphy and serum beta-2-microglobulin, in different stage of the disease for the diagnosis, staging and therapy control by patients with multiple myeloma.
Key words: MULTIPLE MYELOMA. DIAGNOSIS AND THERAPY CONTROL. 99MTC-MIBI SCINTIGRAPHY, SERUM BETA-2-MICROGLOBULIN